Poland· PL-100474874

ROCTAVIAN

A valoctocogene roxaparvovec product containing valoctocogenum roxaparvovecum, registered in Poland by BioMarin International Ltd.. The same ATC class is registered in 6 of our 19 countries.

ATC B02BD15

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedROCTAVIANATCB02BD15REGISTER NO.PL-100474874PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Valoctocogene roxaparvovec is registered in 6 of 19 countries.

Countries holding a registration under ATC B02BD15 (valoctocogene roxaparvovec), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 4 of them publish a price we can compare per daily dose

Valoctocogene roxaparvovec · ATC B02BD15

6 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Valoctocogenum roxaparvovecum
Manufacturer
BioMarin International Ltd.
Country
Poland (PL)
ATC code
B02BD15
ATC class
Valoctocogene roxaparvovec
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Valoctocogene roxaparvovec in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All valoctocogene roxaparvovec products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Roctavian
  • Liechtenstein · Roctavian
  • Norway · Roctavian

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/12e88f85-ac4d-4d0f-8266-52686da35adc
GET /v1/drugs/12e88f85-ac4d-4d0f-8266-52686da35adc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do infuzji",
  "source": "urpl",
  "strength": "2 x 10^13 genomów wektora/ml",
  "packaging": "Rpz ¦ EU/1/22/1668/001 ¦ 148492\n1 fiol. 8 ml",
  "substance": "Valoctocogenum roxaparvovecum 2 x 10^13 genomów wektora/ml",
  "common_name": "Valoctocogenum roxaparvovecum",
  "pl_product_id": "100474874",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about valoctocogene roxaparvovec.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.